PRESENTATION

Q2 2026 — Presentation

Q2 2026PDF · 33 pages2.3 MB
Second-Quarter 2026
Sales and Earnings
Merck & Co., Inc., Rahway, N.J., USA
August 4, 2026

-- 1 of 33 --

Agenda
2
Strategy and Business Update
Robert M. Davis
Chairman and Chief Executive Officer
Agenda
Financial Results and Outlook
Caroline Litchfield
Executive Vice President and Chief Financial Officer
Research Update
Dr. Dean Y. Li
Executive Vice President and President, Research Laboratories
Question & Answer Session

-- 2 of 33 --

Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA
3
This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the
safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and
expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to
pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If
underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost containment; technological advances, new products and patents
attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign
risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future
events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements
can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

-- 3 of 33 --

Strategy and
Business Update
Robert M. Davis
Chairman and Chief Executive Officer
4

-- 4 of 33 --

55
1. Non-risk adjusted annual sales by the mid 2030s 2. Clinically derisked defined as first successful Phase 3 study in a certain indication to read out according to PCD on ct.gov 3. In collaboration with Kelun
Biotech 4. In collaboration with Daiichi Sankyo; FDA PDUFA date October 10, 2026 5. In collaboration with Gilead
Accelerating progress toward transformation of portfolio
As presented January 2026
Mid 2030s revenue opportunity from
current and potential new growth drivers1
>$70B
Increasingly clinically derisked
 2
Additional innovative pipeline programs
remigromig 	tulisokibart
islatravir /
lenacapavir5
MK-1406
sacituzumab
tirumotecan3
ifinatamab
deruxtecan4
Today
2026
2027
2028+
enlicitide

-- 5 of 33 --

66
Accelerating progress toward transformation of portfolio
Progress since January 2026
1. Non-risk adjusted annual sales by the mid 2030s 2. Clinically derisked defined as first successful Phase 3 study in a certain indication to read out according to PCD on ct.gov 3. In collaboration with Kelun
Biotech 4. In collaboration with Daiichi Sankyo; FDA PDUFA date October 10, 2026 5. In collaboration with Gilead
Approved
2026
2027
2028+
Mid 2030s revenue opportunity from
current and potential new growth drivers1
>$70B
Increasingly clinically derisked
 2
Additional innovative pipeline programs
POSITIVE TOPLINE	POSITIVE RESULTS
remigromig 	tulisokibart
islatravir /
lenacapavir5
POSITIVE TOPLINE 	UNDER REVIEW
MK-1406
sacituzumab
tirumotecan3
ifinatamab
deruxtecan4
APPROVED

-- 6 of 33 --

¹Weber Shandwick/KCR Research, 2020 / AMO 2019 	7
$16.6B
Q2 Worldwide Sales
Strength in Oncology and Animal Health
Increasing contributions from new launches
+5% nominal
+4% ex-exchange
1. In collaboration
Achieved significant pipeline and regulatory progress:
• 	Received several approvals for KEYTRUDA and KEYTRUDA QLEX
including one in combination with WELIREG
• 	Presented data at ASCO from multiple novel candidates and broad
oncology portfolio
• 	Announced positive topline results for sac-TMT1 in certain patients
with advanced or recurrent endometrial cancer
Oncology
• 	Announced positive topline results for tulisokibart from induction-
only study of Phase 3 ATLAS-UC
Immunology
• 	Presented data from innovative HIV portfolio at AIDS 2026
including for islatravir/lenacapavir1
Infectious Diseases
• 	FDA approved LIPFENDRA as first and only oral PCSK9i
Cardiometabolic & Respiratory

-- 7 of 33 --

88
Completed strategic acquisition of Terns Pharmaceuticals
Adds MK-4208, an investigational next-generation, allosteric TKI
for treatment of certain patients with chronic myeloid leukemia
Science-driven business development that strengthens and
complements hematology pipeline
Potential best-in-class profile with opportunity to further improve
depth and duration of response in certain patients
Multibillion dollar commercial opportunity and growth driver in
the next decade, creating shareholder value

-- 8 of 33 --

islatravir + ulonivirine
NRTI + NNRTI
V181
Tetravalent dengue vaccine
intismeran autogene4
INT
calderasib3
KRAS G12Ci
patritumab deruxtecan2
HER3 ADC
gocatamig2
DLL3 T-cell engager
MK-1045
CD19xCD3 T-cell engager
raludotatug deruxtecan2
CDH6 ADC
opevesostat
CYP11A1i
MK-8748
Tie2 agonist/VEGFi
2024-25 	2026 	2027 	2028 	2029+
Timing represents approval date for marketed products or announced positive topline results, PDUFA date, or earliest Phase 3 primary completion date according to clinicaltrials.gov for pipeline compounds
1. In collaboration 2. In collaboration with Daiichi Sankyo 3. In collaboration with Taiho Astex 4. In collaboration with Moderna
Pipeline candidates with first-in-class potential
Successfully executing on strategy to broaden and diversify pipeline
9
islatravir / lenacapavir1
NRTI / capsid inhibitor
sacituzumab tirumotecan1
TROP2 ADC
ifinatamab deruxtecan1
B7-H3 ADC
remigromig
Wnt agonist
tulisokibart
TL1A mAb
alimatravir
NRTI
zilovertamab vedotin
ROR1 ADC
nemtabrutinib
BTKi
bomedemstat
LSD1i
MK-1406
zanamivir-Fc conjugate
Cardiometabolic
& Respiratory Infectious Disease 	Oncology 	Immunology 	Ophthalmology

-- 9 of 33 --

Financial Results
and Outlook
Caroline Litchfield
Executive Vice President and
Chief Financial Officer
10

-- 10 of 33 --

11
Q2 growth across human and animal health with increasing contributions
from new products
1. Worldwide Sales includes Other Revenue 2. Launch products include WINREVAIR, KEYTRUDA QLEX, CAPVAXIVE, OHTUVAYRE, ENFLONSIA, IDVYNSO, BRAVECTO QUANTUM and NUMELVI
$16.6B+5% nominal
+4% ex-exchange
WORLDWIDE SALES1
Human Health
$14.8B+5% growth
+4% ex-exchange
Animal Health
$1.8B+8% growth
+5% ex-exchange
2Q25 	2Q26
$1.5B
$0.6B
Launch product revenue2
OHTUVAYRE sales reported by Verona Pharma

-- 11 of 33 --

Oncology: KEYTRUDA continues to benefit patients and drive growth
12
KEYTRUDA family1 sales of $8.4B increased
4% driven by strong uptake in earlier-stage
cancers and robust demand from metastatic
indications
‒ 	Growth driven by usage in tumors
predominantly affecting women, including those
with certain breast and cervical cancers
‒ 	Increased use of KEYTRUDA in combination with
enfortumab vedotin in locally advanced or
metastatic urothelial cancer
‒ 	KEYTRUDA QLEX sales of $463M in 2Q26
following launch in 3Q25; permanent J-code
effective April 1st
2Q24 	2Q25 	2Q26
$7.3B
+21%2
$8.4B
+4%$8.0B
+9%
Growth rates exclude the impact of foreign exchange 1. KEYTRUDA family includes KEYTRUDA and KEYTRUDA QLEX (available as KEYTRUDA SC in some markets) 2. ~4 percentage points of negative
impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market.

-- 12 of 33 --

2Q24 	2Q25 	2Q26
Oncology: Continued impact for patients across broad portfolio
13
WELIREG sales grew 67% driven by continued
higher demand in the U.S. and launch uptake
in international markets
Lynparza 1 alliance revenue relatively flat
compared with prior year
Lenvima 2 alliance revenue grew 6%, primarily
due to higher demand in the U.S., partially
offset by net price
Growth rates exclude the impact of foreign exchange 1. In collaboration with AstraZeneca 2. In collaboration with Eisai
2Q24 	2Q25 	2Q26
$370M
+15%$317M
+4%
$365M
-2%
2Q24 	2Q25 	2Q26
$265M
+5%
$249M
+4%
$283M
+6%
$126M
+150%
$162M
+29% 	$271M
+67%

-- 13 of 33 --

Vaccines & Infectious Diseases: Impacting lives globally
2Q24 	2Q25 	2Q26
2Q24 	2Q25 	2Q26
Growth rates exclude the impact of foreign exchange 1. Launched in 3Q24 2. Launched in 2Q26
GARDASIL sales of $1.2B increased 3% driven
by higher sales in certain international
markets
‒ 	In the U.S., sales were flat primarily due to lower
demand and timing of CDC purchases, largely
offset by price
CAPVAXIVE 1 sales of $184M increased 40%
driven by uptake from ongoing launches in
certain international markets and higher
demand in the U.S.
IDVYNSO2 progress on access and
reimbursement following recent launches
in U.S. and Japan
$184M
+40%
$2.5B
+4%
$129M
$1.1B
-55%
$1.2B
+3%
14

-- 14 of 33 --

Cardiometabolic & Respiratory: Continuing to drive benefit for patients
with successful ongoing launches
WINREVAIR sales of $588M driven by
continued growth in new patient starts and
total prescriptions
‒ 	In the U.S., ~1,800 new patients prescribed and
>34,000 total prescriptions dispensed
‒ 	Ex-U.S., making progress with ongoing launches
OHTUVAYRE 1 sales of $204M reflect
continued prescription demand
‒ 	Benefitted from specialty pharmacy purchase
timing, which is expected to unwind in 3Q26
2Q24 	2Q25 	2Q26
$1.7B
+40%
2Q24 	2Q25 	2Q26
$204M
Growth rates exclude the impact of foreign exchange 1. Ohtuvayre was obtained as part of the acquisition of Verona Pharma on October 7, 2025 2. Sales reported by Verona Pharma
$336M
+381%
$588M
+75%
$103M2
$70M
15

-- 15 of 33 --

Animal Health: Solid growth driven by livestock and companion animal
16
Animal Health sales increased 5% to $1.8B
‒ 	Livestock sales grew 6% driven by higher
demand for ruminant and poultry products
‒ 	Companion Animal sales grew 5% driven by new
product launches
2Q24 	2Q25 	2Q26
$1.5B
+6% 1
$1.6B
+11%
$1.8B
+5%
Growth rates exclude the impact of foreign exchange 1. ~3 percentage points of negative impact of foreign exchange due to devaluation of Argentine peso, which was largely offset by inflation-related price
increases, consistent with practice in that market

-- 16 of 33 --

Q2 2026 non-GAAP financial results summary 1
$ in billions, except LPS / EPS amounts
17
1. The company is providing certain 2026 and 2025 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business
performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee
compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or
superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q2 2026 non-GAAP results include a charge of
$5.7 billion related to the acquisition of Terns Pharmaceuticals, Inc. (Terns). Q2 2025 non-GAAP results include $200 million charge related to the closing of a license agreement with Jiangsu Hengrui
Pharmaceutical Co., Ltd. (Hengrui Pharma). 3. Q2 2026 includes a charge of $2.31 per share related to the acquisition of Terns. Q2 2025 includes a charge of $0.07 per share related to the closing of a license
agreement with Hengrui Pharma. 4. Q2 2026 GAAP LPS of $(0.54).
Q2 2026 	Q2 2025 	Change Change
Ex-FX
Sales 	$16.6 	$15.8 	+5% 	+4%
Non-GAAP Gross Margin 	81.1% 	82.2% 	-1.1 pts 	-1.5 pts
Non-GAAP Operating
Expenses2 	$12.6 	$6.6 	91% 	90%
Non-GAAP Tax Rate 	160.3% 	15.0% 	N/M 	N/A
Non-GAAP (Loss) /
Earnings Per Share3,4 	$(0.13) 	$2.13 	N/M 	N/M

-- 17 of 33 --

18
Updated 2026 financial outlook
1. Guidance does not assume additional significant potential business development transactions
Prior Guidance 	Updated Guidance 	Key Assumptions
Revenue 	$65.8B to $67.0B 	$66.3B to $67.3B • 	Assumes ~1 percentage point positive impact from FX
• 	Now implies +2% to +4% nominal (+1% to +3% ex-FX)
Non-GAAP
Gross Margin Rate ~82.0% 	~81.0% 	• 	Now includes higher inventory reserves
Non-GAAP
Operating Expenses1 	$36.0B to $36.8B 	$42.0B to $42.7B • 	Now includes $5.7B charge related to acquisition of
Terns
Other (Income) / Expense 	~$1.3B of expense 	~$1.4B of expense • 	Incorporates financing costs related to acquisition of
Terns
Tax Rate 	~23.5% to 24.5% 	~35.0% to 36.0% • 	Incorporates impact of non-tax deductible charge for
Terns
Shares Outstanding 	~2.48B 	~2.48B 	• 	Assumes ~$3B of share repurchases
Non-GAAP EPS1 	$5.04 to $5.16 	$2.66 to $2.76 • 	Incorporates ~$2.31 impact related to upfront charge for
acquisition of Terns
• 	Now assumes ~$0.15 positive impact from FX

-- 18 of 33 --

Key modeling considerations
19
• 	Reaching peak penetration in several key
indications
• 	Expect headwind from timing of wholesaler
purchases in 3Q
U.S. KEYTRUDA	OHTUVAYRE
• 	Expect 3Q to be impacted by unwind of 2Q
specialty pharmacy purchases
• 	Expect investments behind sales force and
promotion to drive accelerated growth in
2027
OTHER REVENUE
• 	Expect 2H26 to be significantly higher than
2H25 driven by revenue hedging program and
expected milestone receipt in 4Q
U.S. BRIDION
• 	Anticipate slower than previously expected
sales decline due to lower generic competition

-- 19 of 33 --

Remain committed to balanced capital allocation strategy
Q2 Spend ($ in billions)1
20
1. Reflects quarter spend 2. Reflects R&D excluding Business Development
Augmented our pipeline with
value-enhancing business
development while investing
in our pipeline and business
as well as returning cash to
shareholders
Capital allocation order of priority
$3.4
$0.9
$2.1
$6.3
$0.7
After-Tax R&D² 	CapEx 	Dividends
Paid
Business
Development
(ex-divestitures)
Share Repurchase

-- 20 of 33 --

Research Update
Dr. Dean Y. Li
Executive Vice President and President,
Research Laboratories
21

-- 21 of 33 --

LIPFENDRA the first and only approved oral PCSK9i
22
• 	First FDA-approved oral PCSK9 inhibitor to reduce LDL-C in
adults with hypercholesterolemia, along with diet and exercise
• 	ASCVD remains the leading cause of morbidity and mortality
worldwide
− 	Ongoing CORALreef Outcomes trial evaluating effect of
LIPFENDRA on cardiovascular morbidity and mortality
• 	Currently under review by EMA and China NMPA
• 	Approval further validates macrocyclic peptide platform
• 	Evaluating potential fixed-dose combinations with
rosuvastatin and Lp(a) (MK-7262)
LIPFENDRA

-- 22 of 33 --

23
Advancing innovative longer-acting oral treatment options for people
living with HIV
Islatravir/lenacapavir1
• 	Presented positive results from Phase 3 ISLEND-
1 and ISLEND-2 studies demonstrating ISL/LEN
was effective in adults with virologically
suppressed HIV who switched from BIC/FTC/TAF
or other oral SoC
• 	Data support potential for ISL/LEN to be first
once-weekly oral treatment option
Islatravir/ulonivirine
• 	Presented positive Phase 2b results for ISL+ULO
demonstrating maintenance of viral suppression
in adults with virologically suppressed HIV who
switched from BIC/FTC/TAF
• 	Advancing to Phase 3 in new-to-treatment and
treatment experienced populations of adults
living with HIV
1. In collaboration

-- 23 of 33 --

Important updates across infectious disease programs
24
MK-1406
• 	Phase 3 ANCHOR study completed enrollment in
Southern Hemisphere
• 	Plan to enroll second Northern Hemisphere flu
season to broaden geographic footprint and
support robust global registration strategy
• 	Continue to anticipate potential approval in 2029
CAPVAXIVE
• 	FDA approved expanded indication for children
and adolescents aged 2 through 17 years who are
at increased risk for pneumococcal disease

-- 24 of 33 --

25
Important progress in immunology clinical development program
Tulisokibart
• 	Announced positive topline results of induction-only
study in moderately to severely active ulcerative colitis
• 	First anti-TL1A mAb to demonstrate positive results
in a Phase 3 trial
Broadest TL1A development program
Gastroenterology
Dermatology
Rheumatology
ATLAS-UC
PCD: Aug 2026
Study 2
~300 patients
12-week induction-only
POSITIVE TOPLINE
Study 1
~720 patients
52-week induction and
maintenance
Ongoing

-- 25 of 33 --

26
Continuing to advance cancer care with broad, differentiated portfolio and
pipeline
Positive topline results
• 	KEYNOTE-C93: Announced study evaluating
KEYTRUDA monotherapy met primary endpoint of PFS
for certain patients with advanced or recurrent
endometrial cancer with dMMR tumors versus platinum
doublet chemotherapy
• 	TroFuse-005: Announced study evaluating sac-TMT1
met primary endpoints of OS and PFS in patients with
advanced or recurrent endometrial cancer who have
progressed after platinum-based chemotherapy and
anti-PD-1/L1
− 	First TROP2 ADC to improve OS and PFS compared to
chemotherapy in certain patients with advanced or
recurrent endometrial cancer
− 	First positive readout from 17 global Phase 3 TroFuse
studies
Recent approvals
• 	KEYNOTE-9051 : EC approved KEYTRUDA with
enfortumab vedotin as neoadjuvant treatment and then
continued after radical cystectomy as adjuvant
treatment for resectable cis-ineligible MIBC
• 	KEYNOTE-D191 : FDA approved KEYTRUDA and
KEYTRUDA QLEX each with sacituzumab govitecan for
1L treatment of PD-L1 positive (CPS ≥ 10) unresectable
locally advanced or metastatic TNBC
• 	KEYNOTE-B151 : FDA approved KEYTRUDA and
KEYTRUDA QLEX each with enfortumab vedotin-ejfv as
neoadjuvant treatment and then continued after
cystectomy as adjuvant treatment for the treatment of
MIBC
• 	LITESPARK-022: FDA approved KEYTRUDA and
KEYTRUDA QLEX each with WELIREG for adjuvant
treatment of certain patients with clear cell RCC
− 	13 KEYTRUDA-based regimens now approved in earlier
stage cancer
1. In collaboration

-- 26 of 33 --

Significant late-stage pipeline milestones expected over next six months
27
Oncology
WELIREG
• 	LITESPARK-011 PDUFA date October 4th
I-DXd1
• 	IDeate-Lung01 PDUFA date October 10th
Sac-TMT1
• 	Presentation of detailed findings from Phase 3
TroFuse-005 trial
ESMO Investor Event
• 	Monday, October 26 th at 6 p.m. CET / 1 p.m. ET
Cardiometabolic & respiratory
WINREVAIR
• 	HYPERION PDUFA date September 21st
Immunology
Tulisokibart
• 	PCD in August for Phase 3 ATLAS trial in UC
• 	Presentation of detailed findings from Phase 2
study in HS
Ophthalmology
Remigromig (MK-3000)
• 	PCD in September for Phase 3 BRUNELLO trial
in DME
1. In collaboration

-- 27 of 33 --

Q&A
Robert M. Davis
Chairman and Chief Executive Officer
Dr. Dean Y. Li
Executive Vice President and President, Research Laboratories
Caroline Litchfield
Executive Vice President and Chief Financial Officer
Peter Dannenbaum
Senior Vice President, Investor Relations

-- 28 of 33 --

29
Appendix

-- 29 of 33 --

Q2 2026 GAAP financial results summary
$ in billions, except LPS / EPS amounts
30
Q2 2026 	Q2 2025 	Change 	Change Ex-FX
Sales 	$16.6 	$15.8 	+5% 	+4%
Operating Expenses
(SG&A and R&D)1,2 $12.6 	$6.7 	89% 	88%
Tax Rate 	-95.9% 	11.4% 	N/M 	N/A
GAAP (Loss) / Earnings
per Share1,2 $(0.54) 	$1.76 	N/M 	N/M
1. Q2 2026 GAAP results include a charge of $5.7 billion, or $2.31 negative EPS impact, related to the acquisition of Terns 2. 2Q25 GAAP results include $200 million charge, or $0.07 negative EPS impact,
related to the closing of a license agreement with Hengrui Pharma

-- 30 of 33 --

$13.0 $3.9 $8.3
$26.4
$4.2
$0
$5
$10
$15
$20
$25
$30
After-Tax R&D 	CapEx 	Dividends Paid 	Business
Development
(ex-divestitures)
Share
Repurchase
Capital allocation: Trailing twelve months
31
Capital allocation order of priority
2
1
Executing upon balanced capital allocation strategy
1. Reflects R&D excluding Business Development 2. Includes BD payments reflected in operating cash flow
Over the past 12 months
Committed to the dividend
2017 	2018 	2019 	2020 	2021 	2022 	2023 	2024 	2025 	2026E
Dollars per Share
+2% 	+2%
+15% +11% +7% +6% +6%
+5%
+5%
+5%Capital investments
2026 to 2030
~$19B
Over 5 years, including more than $14B in the U.S.
Well-positioned balance sheet with
capacity to fund additional value-
enhancing business development
opportunities

-- 31 of 33 --

Broad and innovative pipeline to address significant unmet medical needs
32
As of August 4, 2026
Phase 3
Oncology
MK-1022 (patritumab
deruxtecan) 1
Breast
MK-1026 (nemtabrutinib)
Hematological Malignancies
MK-1084 (calderasib) 1
CRC
NSCLC
MK-2140 (zilovertamab
vedotin)
Hematological Malignancies
MK-2400 (ifinatamab
deruxtecan) 1
Esophageal
Prostate
SCLC (EU)
MK-2870 (sacituzumab
tirumotecan) 1
Bladder
Breast
Cervical
Endometrial
Gastric
NSCLC
Ovarian
MK-1406
Influenza
LAGEVRIO (MK-4482) 1,3
COVID-19 (U.S.)
MK-8527 (alimatravir)
HIV-1 PrEP
MK-8591D (islatravir +
lenacapavir) 1,2
HIV-1 Infection
KEYTRUDA (MK-3475)
SCLC
MK-3543 (bomedemstat)
Myeloproliferative Disorders
MK-5684 (opevesostat)
Prostate
MK-5909 (raludotatug
deruxtecan) 1
Ovarian
LYNPARZA (MK-7339) 1
NSCLC
SCLC
V940 (intismeran autogene) 1
Melanoma
NSCLC
Infectious Diseases
MK-1022 (patritumab
deruxtecan) 1
Biliary
Bladder
Cervical
Endometrial
Esophageal
Gastric
HCC
Melanoma
NSCLC
Ovarian
Pancreatic
Prostate
MK-1045
Hematological Malignancies
MK-1084 (calderasib) 1
Solid Tumors
MK-2400 (ifinatamab
deruxtecan) 1
Biliary
Bladder
Breast
Cervical
Endometrial
HCC
HNSCC
Melanoma
NSCLC
Ovarian
Pancreatic
Solid Tumors
MK-2870 (sacituzumab
tirumotecan) 1
Biliary
Esophageal
Neoplasm Malignant
Pancreatic
Oncology
Infectious Diseases
MK-8591B (islatravir +
ulonivirine)
HIV-1 Infection
MK-5475 (frespaciguat)
PH-COPD
MK-5884A (ensifentrine +
glycopyrrolate)
COPD
MK-6024 (efinopegdutide)
MASH
MK-7262
Atherosclerosis
WINREVAIR (MK-7962)
Pulmonary Hypertension due
to Left Heart Disease
Cardiometabolic &
Respiratory
MK-7240 (tulisokibart)
Axial Spondyloarthritis
Hidradenitis Suppurativa
Psoriatic Arthritis
Rheumatoid Arthritis
Systemic Sclerosis
MK-8690
Ulcerative Colitis
Immunology
MK-3120
Bladder
KEYTRUDA (MK-3475)
Prostate
KEYTRUDA QLEX (MK-3475A)
Hematological Malignancies
(U.S.)
MK-5684 (opevesostat)
Breast
Endometrial
Ovarian
MK-5909 (raludotatug
deruxtecan) 1
Cervical
Endometrial
Gastric
NSCLC
RCC
SCLC
MK-6070 (gocatamig) 1
SCLC
WELIREG (MK-6482)
Breast
V940 (intismeran autogene) 1
Bladder
RCC
MK-2214
Alzheimer’s Disease
Neuroscience
Under regulatory review
Oncology
MK-2400 (ifinatamab deruxtecan) 1
Previously Treated Extensive-Stage SCLC
(U.S.)
KEYTRUDA (MK-3475)
Cisplatin Eligible MIBC (EU, JPN)
Cisplatin Ineligible MIBC (JPN)
Newly Diagnosed High-Risk Endometrial (EU)
Platinum-Resistant Recurrent Ovarian (JPN)
WELIREG (MK-6482)
Clear Cell RCC Following Nephrectomy (EU) 5
Previously Treated Advanced RCC (U.S., EU,
JPN) 1,6
MK-7240 (tulisokibart)
Crohn’s Disease
Ulcerative Colitis
Immunology
MK-3000 (remigromig) 4
Diabetic Macular Edema
MK-8748 4
Neovascular Age-Related
Macular Degeneration
Ophthalmology 	V181
Dengue Fever Virus
Vaccines
Phase 3	Phase 2
Infectious Diseases
IDVYNSO (MK-8591A)
HIV-1 Infection (EU)
Cardiometabolic &
Respiratory
LIPFENDRA (MK-0616)
Primary Hypercholesterolemia or Mixed
Dyslipidemia (EU)
WINREVAIR (MK-7962)
Pulmonary arterial hypertension (U.S.)
1. Being developed in a collaboration 2. On FDA partial clinical hold for higher doses of islatravir than those used in current clinical trials 3. Available in the U.S. under Emergency Use Authorization, which will
terminate effective June 29, 2027 4. Program is in Phase 2/3 studies 5. Under review for combination use with KEYTRUDA 6. Under review in Japan for Lenvima, used in combination with WELIREG

-- 32 of 33 --

33
ADC = Antibody-drug conjugate
ASCO = American Society of Clinical Oncology
ASCVD = Atherosclerotic cardiovascular disease
B7-H3 = B7 homolog 3
BIC/FTC/TAF = bictegravir/emtricitabine/tenofovir
alafenamide
BTKi = Bruton Tyrosine Kinase inhibitor
CDH6 = Cadherin-6
COPD = Chronic obstructive pulmonary disease
CPS = Combined positive score
CRC = Colorectal cancer
CYP11A1 = Cytochrome P450 Family 11 Subfamily A
Member 1
DLL3 = Delta-like ligand 3
dMMR = Deficient DNA mismatch repair
DME = Diabetic macular edema
EC = European Commission
EMA = European Medicines Agency
ESMO = European Society for Medical Oncology
HCC = Hepatocellular carcinoma
Acronyms
OS = Overall survival
PCD = Primary completion date
PCSK9 = Proprotein convertase subtilisin/Kexin type
9
PD-1/PD-L1 = Programmed cell death protein-
1/Programmed cell death ligand-1
PDUFA = Prescription Drug User Fee Act
PFS = Progression free survival
RCC = Renal cell carcinoma
ROR1 = Receptor tyrosine kinase-like orphan receptor
1
SCLC = Small cell lung cancer
SoC = Standard of care
TIE2 = Tyrosine kinase with immunoglobulin-like and
EGF-like domains 2
TKI = Tyrosine kinase inhibitor
TL1A = Tumor Necrosis Factor-like Ligand 1A
TNBC = Triple negative breast cancer
TROP2 = Trophoblast cell surface antigen-2
UC = Ulcerative colitis
ULO = ulonivirine
VEGF = Vascular endothelial growth factor
HER3 = Human epidermal growth factor receptor 3
HIV-1 = Human Immunodeficiency Virus Type 1
HNSCC = Head and neck squamous cell carcinoma
I-DXd = Ifinatamab deruxtecan
INT = Individualized neoantigen therapy
ISL = islatravir
KRAS = Kirsten rat sarcoma viral oncogene homolog
LDL-C = Low-density lipoprotein cholesterol
LEN = lenacapavir
Lp(a) = Lipoprotein(a)
LSD1 = Lysine specific demethylase 1
mAb = Monoclonal antibody
MASH = Metabolic Dysfunction-Associated
Steatohepatitis
MIBC = Muscle invasive bladder cancer
NSCLC = Non-small cell lung cancer
NMPA = National Medical Products Administration
NRTI = Nucleoside reverse transcriptase inhibitor
NNRTI = Non-nucleoside reverse transcriptase
inhibitor

-- 33 of 33 --